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ABSTRACT
Extracellular vesicles (EVs) are a heterogeneous group of small secreted particles involved in inter-
cellular communication and mediating a broad spectrum of biological functions. EVs cargo is
composed of a large repertoire of molecules, including glycoconjugates. Herein, we report the first
study on the impact of the isolation strategy on the EV populations’ glycosylation profile. The use of
different state-of-the-art protocols, namely differential ultracentrifugation (UC), total exosome isola-
tion (TEI), OptiPrepTM density gradient (ODG) and size exclusion chromatography (SEC) resulted in EV
populations displaying different sets of glycoconjugates. The EV populations obtained by UC, ODG
and SECmethods displayed similar protein and glycan profiles, whereas TEI methodology isolated the
most distinct EV population. In addition, ODG and SEC isolation protocols provided an enhanced EV
glycoproteins detection. Remarkably, proteins displaying the tumour-associated glycan sialyl-Tn
(STn) were identified as packaged cargo into EVs independently of the isolation methodology. STn
carrying EV samples isolated by UC, ODG and SEC presented a considerable set of cancer-related
proteins that were not detected in EVs isolated by TEI. Our work demonstrates the impact of using
different isolation methodologies in the populations of EVs that are obtained, with consequences in
the glycosylation profile of the isolated population. Furthermore, our results highlight the importance
of selecting adequate EV isolation protocols and cell culture conditions to determine the structural
and functional complexity of the EV glycoconjugates.
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Introduction
Extracellular vesicles (EVs) are cell-derived structures
that emanate from practically all cell types, both in vivo
and in vitro [1]. After cell membrane release, EVs
transporting specific cargo between cells, including
cancer cells, contribute to horizontal reprogramming
and functional re-education of recipient cells [2,3].
Three main classes of EVs have been widely described:
exosomes, originating from the inward budding of
endosomal membrane during maturation of multivesi-
cular endosomes (ranging between 40 and 150 nm in
size); microvesicles, which are shed from the plasma
membrane (ranging between 50 and 2000 nm); and
apoptotic-bodies, that are released upon fragmentation
of cells undergoing apoptosis (ranging between 50 and
5000 nm) [4]. Recently, a new and smaller cell-derived
population called exomeres has been identified and
fully characterized, with a smaller size of 35 nm in
average [5]. Up to this date, EVs are known to carry
a broad repertoire of cargoes, including proteins (e.g.
cytokines, membrane receptors, receptor ligands),
nucleic acids (e.g. DNA, mRNA, long and short non-
coding RNA), lipids and glycans [1,5–7].
Glycosylation is the most abundant post-translational
modification of proteins, and its functional roles provide
the basis for several pathophysiological processes, reveal-
ing to be crucial in complex diseases, such as cancer.
Tumour cells express a wide variety of glycosylation
alterations, which interfere with key cancer cell processes
and with the tumour microenvironment, contributing to
cancer progression and patients’ poor prognosis [8].
Particularly, the cancer-associated glycan sialyl-Tn
(STn) has been shown to be highly related with tumour
cell aggressive features, cancer metastasis and patients’
poor survival [9–14]. This truncated structure results
from a deregulation of the O-glycosylation biosynthetic
CONTACT Celso A. Reis celsor@ipatimup.pt; Ana Magalhães amagalhaes@ipatimup.pt i3S-Institute for Research and Innovation in Health,
University of Porto, Porto, Portugal
*These authors contributed equally to this work.
Supplemental data for this article can be accessed here.
JOURNAL OF EXTRACELLULAR VESICLES
2019, VOL. 8, 1621131
https://doi.org/10.1080/20013078.2019.1621131
© 2019 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group on behalf of The International Society for Extracellular Vesicles.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/), which
permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
pathway, such as overexpression of ST6GalNAc1 enzyme
[15,16] or loss of function of Cosmc chaperone [17,18].
STn is overexpressed in several cancer types [16,19–23],
although its detection is rare or absent in healthy adult
tissue [24–26].
Despite the recent increase in the number of studies on
EVs, the ones addressing the role of its glycosylation are
scarce. Previous reports have described that glycoconju-
gates are important regulators of exosomes biogenesis
[27] as well as being critical players in the recognition
and the uptake of exosomes by the recipient cells [28–33].
Moreover, it has been shown that N-glycosylation directs
the sorting of glycoproteins into exosomes [28].
Considering that cancer cells shed EVs displaying diverse
glycosylation profiles [5,34], it is of great importance to
characterize the EV glycan content and its functional
implications in cancer. Previous studies demonstrated
the impact of using different isolation methodologies in
the yield and the purity of EVs from either cell culture
supernatant or plasma samples with consequences in the
further protein and/or RNA analyses [35–39].
Consequently, a strong effort has been done to standar-
dize EV isolation protocols. Despite the recent evidences
showing that glycans are critical players in EVs biology, to
date, the effect of using different EV isolationmethods for
glycan analysis has never been reported.
In the present study, we assessed the impact on EVs
glycosylation profile of different state-of-the-art isola-
tion methodologies, namely differential ultracentrifu-
gation (UC), total exosome isolation (TEI),
OptiPrepTM density gradient (ODG) and size exclusion
chromatography (SEC), as well as the implications of
FBS in the cell culture medium on the downstream
analysis (Figure 1). The use of a genetically engineered
gastric cancer cell line displaying truncated
O-glycosylation allowed us to isolate EVs containing
the tumour-associated glycan STn.
Methods
Cell lines and culture conditions
The human gastric cancer cell line MKN45 (Japanese
Collection of Research Bioresources) and the previous
established glycoengineered MKN45 [40] were cultured
in RPMI GlutaMAXTM, HEPES medium supplemented
with 10% FBS and 1% penicillin-streptomycin (all from
Invitrogen, Carlsbad, CA, USA) and maintained at 37ºC
in an atmosphere of 5% CO2. EVs collection was per-
formed after culturing cells for 48 h with medium with-
out FBS or with medium supplemented with 10% of EVs-
depleted FBS. The FBS was depleted of bovine EVs by
ultracentrifugation at 100,000 g for 16 h [41]. Cultured
cells were routinely tested for mycoplasma contamination
and cell line identity was confirmed by STR profiling.
Immunofluorescence
Cells were grown in Ibidi slides (Planegg, Germany) for
48 h using medium with and without FBS supplemen-
tation. Cells were fixed with 4% paraformaldehyde
(Alfa Aesar, Haverhill, MA, USA) at RT for 20 min
and permeabilized with 0.5% TritonTM X-100 (Sigma-
Aldrich, Saint Louis, MO, USA) in PBS at 4ºC for 10
min. Double staining with STn (TKH2) [26] and actin
(I-19) (Santa Cruz Biotechnology, Dallas, TX, USA)
was performed as follows. First, a blocking step with
non-immune goat serum (Dako, Agilent, Santa Clara,
CA, USA) diluted 1/5 in PBS 10% BSA was performed.
Then, anti-STn antibody diluted 1/5 overnight at 4ºC
and anti-mouse conjugated with Alexa Fluor® 488
diluted 1/500 in PBS, 5% BSA. Thereafter, antibody
anti-actin diluted 1/150 in PBS containing 5% BSA,
followed by anti-rabbit Alexa Fluor® 594 diluted 1/500
in PBS containing 5% BSA. Single immunofluorescence
with the biotinylated L-PHA lectin (Vector
Laboratories, Burlingame, CA, USA) was performed
by blocking with PBS, 10% BSA, the lectin diluted 1/
500 in PBS overnight at 4ºC and FITC-conjugated
streptavidin diluted 1/1000 in PBS. DAPI was used
for nuclear staining at RT for 10 min and slides were
mounted in VectaShield (Vector Laboratories,
Burlingame, CA, USA). All incubation steps were per-
formed at RT for 1 h or otherwise specified. Images
were acquired with a Confocal Leica TCS SP5 II (Leica
Microsystems, Wetzlar, Germany) using Leica LAS AF
software version 2.6.0.7266 (Leica Microsystems).
Viability assay
The effect on cell viability produced by FBS removal
from the culture medium was determined by cell pro-
liferation assay (CellTiter 96® AQueous One Solution
Cell Proliferation Assay, Promega, Madison, WI, USA).
We seeded 120,000 cells/mL of MKN45 and glycoengi-
neered MKN45 cell lines in 96-well plates. After reach-
ing 80% confluence, cells were PBS washed and
cultured with medium supplemented with 10%, 5%,
1% and 0% FBS. Treatment with 1 mM H2O2 was
performed as positive control of the assay, since H2O2
induces cell death. After 48 h, 20 µL of 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium (MTS) was added to
the medium, incubated for 2 h and absorbance was
read at 490 nm in an automated microplate reader
(BioTek, Winooski, VT, USA). The quantity of MTS
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formazan product, measured by absorbance at 490 nm,
is directly proportional to the number of living cells in
culture. Two independent experiments with three repli-
cates for each condition were performed.
Isolation of extracellular vesicles by
ultracentrifugation
EVs were obtained by differential centrifugation by
collecting the media, spin at 800 g for 5 min,
followed by a centrifugation at 2,000 g for 10 min.
The supernatant was filtered using a 0.22 µm con-
stant pore filtration system (Corning, New York, NY,
USA). Media was centrifuged for 16 h in
a polyallomer centrifuge tube (Beckman Coulter,
Fullerton, CA, USA) at 100,000 g and 4ºC in
a swinging bucket rotor (Optima XPN-80, SW 55
Ti rotor, Beckman Coulter). A washing step with
saline solution (0,9% of NaCl) was performed for
2 h at 100,000 g and 4ºC. Pellets were resuspended
in saline solution.
Figure 1. Schematic representation of the four methodologies applied for extracellular vesicles (EVs) isolation and further EV
profiling and glycosylation characterization. EVs were isolated by ultracentrifugation (UC), total exosome isolation (TEI), OptiPrepTM
density gradient (ODG) and size exclusion chromatography (SEC) methodologies. ODG and SEC were applied after UC washing step
(EVs*). TEI solution was applied directly to the conditioned medium (without previous UC).
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Isolation of extracellular vesicles by total exosome
isolationTM
TEI was performed according to the manufacturer´s
instructions (Invitrogen). Briefly, media was collected
and centrifuged at 2,000 g, 4ºC for 30 min. The super-
natant was then filtered using 0.22 µm constant pore
filtration system (Corning, New York, NY, USA). The
supernatant was mixed with TEI solution (2:1) by vor-
texing and incubated overnight at 4ºC. EVs were spun
down by centrifugation at 10,000 g and 4ºC for 1 h. The
supernatant was discarded and the pellet resuspended in
saline solution (0,9% of NaCl). According to the manu-
facturer, this method forces less soluble components,
such as EVs, out of solution, by tying up water
molecules.
Isolation of extracellular vesicles by OptiPrepTM
density gradient
A discontinuous iodixanol gradient was prepared as
described [42]. Briefly, solutions of 5%, 10%, 20% and
40% iodixanol were made by mixing a homogenization
buffer [0.25 M sucrose, 10 mM Tris-HCl, pH 7.5] and
OptiPrepTM 60% (w/v) aqueous iodixanol solution. The
gradient was formed by layering 3 mL of 40%, 3 mL of
20%, 3 mL of 10% and 2.5 mL of 5% solutions on top
of each other in a 16.8 mL open top polyallomer tube
(Beckman Coulter). After differential ultracentrifuga-
tion, the pellet obtained after the 2 h washing step was
resuspended in 500 µL of saline solution (0,9% of
NaCl) and overlaid on top of the gradient. An extra
5 mL of saline solution was added on top of the
gradient to reach the volume required to fill the
tubes. Tubes were centrifuged at 100,000 g and 4ºC
for 16 h (SW 32.1 Ti rotor, Beckman Coulter). From
the top to the bottom, the first 5 mL was collected as
fraction 0 and the following 12 mL as independent
fractions of 1 mL each. Fraction 0 was not analysed
as it corresponds to the extra 5 mL of saline solution.
Each of the 12 fractions were weight scaled for density
assessment and syntenin-1 was used to evaluate the
EVs presence (Figure 2). These results were used to
determine the density of fractions to be collected for
EVs further analysis. Fractions containing the EVs
were pooled together after the 16 h spin, diluted with
2 mL of saline solution and concentrated by ultrafiltra-
tion using 10K Amicon Ultra-15 centrifugal filter units
(EMD Millipore, Burlington, MA, USA).
Isolation of extracellular vesicles by size exclusion
chromatography
SEC was performed according to the manufacturer’s
instructions of the qEV column (Izon, Christchurch,
New Zealand). Briefly, after differential ultracentrifuga-
tion, the pellet obtained after the 2 h washing step was
resuspended in 500 µL of saline solution (0,9% of
NaCl) and overlaid on top of the qEV column.
A total of 25 fractions of 500 µL were collected.
Fractions from 6 to12 were collected, and the fractions
7 to 12 were pulled together. Samples were concen-
trated by ultrafiltration with 10K Amicon Ultra-15
centrifugal filter units (EMD Millipore).
Nanoparticle tracking analysis
Nanoparticle tracking analysis (NTA) was performed
according to manufacturer’s instructions using
a NanoSight NS300 system (Malvern Technologies,
Malvern, UK) configured with a Blue 488 laser and
a high sensitivity scientific sCMOS camera. For NTA
analysis of the EVs, saline solution (0,9% of NaCl) was
used as diluent, a syringe pump with constant flow
injection was used and three videos of 60 s were
Figure 2. Representative example of the 12 fractions obtained by OptiPrepTM density gradient. Fractions were weight scaled for
density evaluation and syntenin-1 expression was assessed. Fractions 6 and 7 showed a density of approximately 1.1 g/mL and the
highest expression of syntenin-1 extracellular vesicle marker.
4 D. FREITAS ET AL.
captured with 749 frames and camera level at 13–16.
The videos were recorded and analysed with NTA soft-
ware version 2.3 to determine the size and concentra-
tion of the particles.
Negative-staining transmission electron
microscopy
EVs size, morphology and integrity were visualized by
transmission electron microscopy (TEM) using nega-
tive staining. For this, 10 µL of sample solution was
mounted on Formvar/carbon film-coated mesh nickel
grids (Electron Microscopy Sciences, Hatfield, PA,
USA). The excess liquid was removed with filter
paper, and 10 µL of 1% uranyl acetate was added
onto the grids. Visualization was carried out on
a JEOL JEM 1400 TEM at 120 kV (Tokyo, Japan).
Images were digitally recorded using a CCD digital
camera (Orious 1100W Tokyo, Japan).
Analysis of protein and glycan expression by
western and lectin blotting
EV samples were resuspended in RIPA lysis buffer supple-
mented with 1 mM sodium orthovanadate, 1 mM PMSF
and protease inhibitor cocktail (Roche, Basel, Switzerland)
for 30min on ice, followed by centrifugation at 16,000 g for
20 min. Silver staining was used to adjust protein amounts
loaded per sample. SDS-PAGEof equal amounts of protein
followed by electrophoretic transfer into nitrocellulose
membranes (GE Healthcare, UK) was performed.
Membranes were protein blocked and then incubated
with the following antibodies: rabbit anti-CD9 (EXOAB-
CD9A-1), rabbit anti-HSP70 (EXOAB-Hsp70A-1), rabbit
anti-CD63 (EXOAB-CD63A-1), rabbit anti-CD81
(EXOAB-CD81A-1) (1/1000, all from ExoAb Antibody
Kit, Systems Biosciences, Palo Alto, CA, USA), mouse
anti-Alix (1A12), mouse anti-syntenin-1 (S-31) and
mouse anti-cytochrome C (7H8) (1/200, all from Santa
Cruz Biotechnology). For glycan detection, membranes
were incubated with an anti-STn antibody (TKH2) [26]
and the following biotinylated lectins Aleuria aurantia
lectin (AAL), Phaseolus vulgaris leucoagglutinin (L-PHA)
and Phaseolus vulgaris erythroagglutinin (E-PHA) (all lec-
tins were purchased from Vector Laboratories,
Burlingame, CA, USA, and used at 1/2000 dilution and 1/
1000 dilution for L-PHA). The corresponding HRP-
conjugated secondary antibodies and the Vectastain Elite
ABCHRPKit (Vector Laboratories) were used for primary
antibodies and lectins recognition, respectively.
Chemiluminescence signal was obtained using ECL detec-
tion reagent (GE Healthcare Life Sciences). The total pro-
tein profile of the samples was assessed in parallel on
a silver-stained gel. A control was performed by collecting
the pellet obtained fromcell culturemedium supplemented
with 10%FBS (EVs-depleted) andwithout cell contact. The
glycan recognition of each lectin is as follows: AAL,
Fucα6GlcNAc, Fucα3GlcNAc and Fucα2Gal; L-PHA,
Galβ4GlcNAcβ6(Galβ4GlcNAcβ2)Manα6; E-PHA, Galβ4
GlcNAcβ2Manα6(GlcNAcβ4)(Galβ4GlcNAcβ2Manα3)
Manβ4. (Abbreviations: Fuc, fucose; GlcNAc, N-acet
ylglucosamine; Man, mannose; Gal, galactose; GalNAc,
N-acetylgalactosamine).
Mass spectrometry for protein identification of
silver-stained bands
After silver staining of equal amounts of protein lysate
from EVs, representative bands were selected and
excised from the gel and washed with 50% acetonitrile
in 50 mM ammonium bicarbonate. Reduction and
alkylation were sequentially performed with 25 mM
DTT at 56ºC and 55 mM IAA at RT in the dark,
both for 20 min. Proteins were digested with 20 ng of
trypsin for 3 h at 37ºC in the presence of 0.01% sur-
factant (Promega). The resulting peptides were ana-
lysed on a MALDI mass spectrometer (4800 Plus
MALDI TOF/TOF Analyzer, SCIEX) as described in
[43]. Proteins were identified by Peptide Mass
Fingerprint using the Mascot software v2.6.1 (Matrix
Science, London, UK). Protein searches were per-
formed against the UniProt protein sequence database
for the Homo sapiens and Bos taurus taxonomic selec-
tions (2017_11). The established search parameters
were: maximum of two missed trypsin cleavages,
cysteine carbamidomethylation (fixed modification)
and methionine oxidation (variable modification).
The peptide tolerance was 25 ppm.
Sample preparation for proteomic analysis
Equal amounts of EVs were digested in a lysis buffer
containing 0.6% RapiGest, 1 mM sodium orthovanadate,
1 mM PMSF and protease inhibitor cocktail. The lysed
material was left on ice for 30 min with occasional
vortexing followed by centrifugation (16,000 g for 10
min and 4ºC). The cleared lysate was heated at 80°C,
10 min followed by reduction with 5mM DTT at 60°C,
30 min and alkylation with 10mM IAA at RT for 30 min
before overnight digestion at 37°C with 5 µg trypsin
(Roche). The RapiGest was quenched by adding 2 µL
trifluoroacetic acid, 37°C, 20 min and cleared by centri-
fugation at 10,000 g, 10 min. The cleared acidified
digests were purified by in-house packed Stage tips
(Empore disk-C18, 3M).
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Mass spectrometry for proteomic analysis
EASY-nLC 1000 UHPLC (Thermo Scientific) interfaced
via nanoSpray Flex ion source to an Orbitrap Fusion/
Lumos mass spectrometer (Thermo Scientific) was used
for the proteomic study. A precursor MS1 scan (m/z
350–1,700) of intact peptides was acquired in the
Orbitrap at a nominal resolution setting of 120,000. The
15 most abundant multiply charged precursor ions in the
MS1 spectrum at a minimum MS1 signal threshold of
50,000 were triggered for sequential Orbitrap HCD-MS2
(m/z of 100–2,000). MS2 spectra were acquired at
a resolution of 50,000. Activation time for HCD fragmen-
tation was 30min. Isolation width was 1.6mass units, and
1 microscan was collected for each spectrum. Automatic
gain control targets were 1,000,000 ions for OrbitrapMS1
and 100,000 for MS2 scans. Dynamic exclusion for 60
s was used to prevent repeated analysis of the same
components. Polysiloxane ions at m/z 445.12,003 were
used as a lock mass in all runs.
For the analysis, data processing was performed
using Proteome Discoverer 2.2 software (Thermo
Scientific) using Sequest HT Node. All spectra were
initially searched with full cleavage specificity, filtered
according to the confidence level (medium, low and
unassigned) and further searched with the semi-
specific enzymatic cleavage. In all cases, the precursor
mass tolerance was set to 6 ppm and fragment ion mass
tolerance to 20 mmu. Carbamidomethylation on
cysteine residues was used as a fixed modification.
Methionine oxidation was used as variable modifica-
tions. All spectra were searched against a concatenated
forward/reverse human-specific database (UniProt,
January 2013, containing 20,232 canonical entries and
another 251 common contaminants) using a target
false discovery rate (FDR) of 1%. FDR was calculated
using target decoy PSM validator node. The resulting
protein list was filtered to include only proteins identi-
fied by the minimum of two peptides. The identified
list of proteins in each sample was used to plot a Venn
diagram [44]. Proteins highlighted in the Venn dia-
gram were selected based on known relevance in
human cancer or as EV markers. The proteins identi-
fied by MS were analysed using NetOGlyc 4.0 Server
[45] to predict the presence of O-glycosylation sites.
Statistical analysis
Mean comparison of the variables was performed using
the SPSS statistical software for Windows (version 19;
SPSS Inc., Chicago, IL, USA). After tested for normal-
ity and homoscedasticity using the Shapiro-Wilk and
Levene’s tests, differences among the non-normally
mean values were analysed by Kruskal-Wallis test.
P > 0.05 was considered non-statistically significant.
EV-TRACK
We have submitted all relevant data of our experiments
to the EV-TRACK knowledgebase (EV-TRACK ID:
EV190018) [46].
Results
MKN45 and glycoengineered MKN45 secrete
extracellular vesicles with variable size depending
on the EV isolation approach applied
In this study, we used a genetically engineered gastric
cancer cell line displaying simplified truncated homoge-
neous O-glycosylation, whereas the wild type cell line pre-
sents a heterogeneous glycosylation profile, due to
O-glycosylation extension (Figure 3(a)). Taking into con-
sideration that FBS carries many glycosylated proteins,
which could interfere with further EVs glycosylation ana-
lysis [47], we have first evaluated the impact of FBS
removal on the cell culture medium. We then analysed
the cell glycosylation profile and the morphological fea-
tures after 48 h without serum supplementation and com-
pared with cells cultured with medium supplemented with
10% FBS. As expected, the gMKN45 showed homoge-
neous expression of the O-glycan truncated structure
STn, and this expression was not altered by FBS depletion
(Figure 3(b)). In addition, no major changes in
N-glycosylation were observed after FBS removal, as
detected by L-PHA staining which recognizes branched
N-glycans (Figure 3(b)). Furthermore, no significant
alterations in cell viability were observed when comparing
cells grown in the presence or absence of FBS (Figure 3(c)).
However, the lack of FBS led to the acquisition of a more
elongated cellular phenotype in both cell models, which
was more marked in the gMKN45 (Figure 3(b)).
EVs isolation was performed using four different meth-
odological approaches, namely UC, TEI, ODG and SEC,
from both cell lines either in the presence or in the absence
of FBS. EVs characterization by NTA and TEM revealed
the size and concentration heterogeneity depending on the
different isolation technique applied within each cell line
(Figure 4 and Supplementary Table 1). Although a trend
towards less and smaller particles was observed in
gMKN45 when compared to MKN45, UC, ODG and
SEC methods resulted in similar particle concentration
for the same cell line growing in the absence of FBS
(Supplementary Table 1). The particle size and concentra-
tion assessed by NTA revealed that in the presence of FBS,
EV samples obtained from MKN45 and gMKN45 were
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more alike when isolated by the same method.
Noteworthy, TEI protocol resulted in comparable concen-
tration of isolated particles as the other methods using less
starting volume, especially in the presence of FBS (Figure 4
and Supplementary Table 1).We cannot exclude that these
results may reflect the presence of non-EV contaminants
that co-precipitated when applying TEI methodology.
Extracellular vesicles display different protein profile
depending on the isolation methodology applied
EVs were successfully isolated from both MKN45 and
gMKN45 cell lines using the four aforementioned meth-
odologies. Silver staining was used for total protein profile
analysis and as protein loading control (Figure 5). The
total protein profile of the two cell lines was similar
whenever the same methodology and culture condition
were applied. However, the different EV isolation meth-
odologies affected the protein profile obtained for both
cell lines. Moreover, the presence or the absence of FBS in
the culture medium also showed to impact the total
protein profiles for both MKN45 and gMKN45 cell
lines. In particular, TEI led to the largest co-isolation of
BSA and ODG to the least (Figure 5). The band around
65 kDa was identified by MS as BSA (Figure 5). Some
additional contaminant bovine proteins were detected in
the EV samples isolated from the cells cultured with
medium supplemented with FBS (Figure 5). In the EV
Figure 3. Effects of FBS depletion in morphology and viability of MKN45 and glycoengineered MKN45 human gastric cancer cell
lines. (a) Schematic depiction of STn biosynthesis. Increased expression of ST6GalNAc1 enzyme or mutations on COSMC gene
preclude elongation of the O-glycosylation. (b) Cells grown in the absence (-FBS) or presence (+FBS) of FBS in the culture medium
were fixated and stained with STn (green) and actin (red) antibodies and L-PHA (green) lectin. Nuclei were stained with DAPI (blue).
Images were taken with a confocal microscope. Scale bar represents 10 µm. Brightfield pictures acquired in an inverted microscope
show the differences in cell morphology. Scale bar represents 50 µm. (c) Comparison of viable cells in proliferation when subjected
to culture medium supplemented with different percentages of FBS for 48 h. Boxplot represents the values corresponding to the
absorbance at 490 nm corrected by the blank. Two independent experiments with triplicates were conducted. As positive control,
1 mM H2O2 was added to the cells. Statistical analysis was calculated with Kruskal-Wallis test: MKN45 p = 0.212 and gMKN45 p =
0.244; p-value > 0.05 was considered non-significant. Abbreviations: FBS: fetal bovine serum; L-PHA: Phaseolus vulgaris leucoagglu-
tinin; STn: sialyl-Tn.
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samples collected from non-supplemented medium,
common EV markers, such as syntenin-1 or CD9, were
detected byMS (Figure 5), and then validated byWestern
blot in both culture conditions (Figure 6(a,b)).
The common EV markers heat shock protein 70
(HSP70) and syntenin-1 were detected in all populations
of secreted vesicles, independently on the methodology
applied (Figure 6(a,b)). All samples also showed the
absence of the cell organelle-specific marker cytochrome
C (Figure 6(a,b)). Depending on the isolation methodol-
ogy applied, differences in the EV markers were
detected. The UC, ODG and SEC protocols isolated
EV populations carrying HSP70, syntenin-1, CD9,
CD83, Alix and CD81 markers independently of the
culture condition; however, CD9, Alix and CD81 were
differentially expressed in MKN45 and gMKN45 cell
lines (Figure 6(a,b)). CD9 protein was not detected by
western blotting in the EVs isolated by TEI protocol
independently of the cell line or the culture condition
used as well as for CD63 and CD81 when EVs were
isolated in the absence of FBS (Figure 6(a,b)). We per-
formed TEI either after UC or ODG, and our results
showed that TEI was able to isolate EVs positive for
CD63 and CD9 only if the samples were previously
submitted to UC or ODG (Figure 6(c)). Altogether,
TEI seems to have a weak selectivity in precipitating
EVs, being the enrichment strongly influenced by the
complexity of the sample. Therefore, when applied
directly to cell culture medium TEI co-precipitates addi-
tional non-EV proteins, precluding the detection by
western blotting of EV markers, such as the tetraspanins
CD9, CD63 or CD81 (Figure 6(a,b)). The different
Figure 4. Characterization of extracellular vesicles isolated by differential ultracentrifugation (UC), total exosome isolation (TEI),
OptiPrepTM density gradient (ODG) and size exclusion chromatography (SEC) methodologies using NTA analysis and transmission
electron microscopy (TEM) imaging, including lower magnification (left) and zoomed in pictures (right). Extracellular vesicles were
collected from MKN45 and glycoengineered MKN45 (gMKN45) cell lines cultured in the absence (-FBS) or presence (+FBS) of FBS in
the cell culture medium. At least two independent experiments were conducted. NTA graphs display in y-axis: concentration (in 106
particles/mL) and in x-axis: size (nm). TEM images: Scale bar represents 400 nm (left TEM panel) and 100nm (right TEM panel),
respectively.
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protein cargo isolated by TEI is also demonstrated by
the specific protein profile observed by silver staining
(Figure 5). Overall, different isolation methods resulted
in EV subpopulations carrying different proteins.
Distinct extracellular vesicle glycosylation profiles
are obtained depending on the isolation technique
applied
A panel of glycan recognizing lectins and a specific
antibody for the STn glycan structure were used to
analyse the glyco-cargo of the EVs obtained by apply-
ing different isolation techniques.
The cancer-associated STn simple O-glycan, as
expected, showed to be expressed in the total extract of
the gMKN45 cell line and absent in the MKN45 parental
cells (Figure 7(a)) [40,45]. Remarkably, this modification
on the cells had an impact on the isolated EVs. STn
antigen showed to be highly present in the glycoproteins
carried by the EVs isolated from the gMKN45 cells, and
being absent in the EV glycoproteins derived from the
MKN45 parental cell line. Furthermore, a high molecu-
lar weight set of STn carrying glycoproteins were pre-
ferentially packaged into EVs when compared with the
whole gMKN45 cellular lysate (Figure 7(a)). Moreover,
strong differences were observed in the STn positive
proteins enriched in the gMKN45 EVs depending on
the applied methodology. In particular, TEI protocol
resulted in the most distinct STn staining profile, with
very low levels of STn detected in the EVs isolated by
TEI from cells cultured in the presence of FBS (Figure
7(a)).
Similar to what we observed regarding the protein
content, the presence or the absence of FBS in the
culture medium also showed to affect the detection of
glycosylated proteins for both MKN45 and gMKN45
cell lines. In order to assess these glycosylation changes
in the EV profile, three lectins detecting cancer relevant
Figure 5. Identification by MS of representative proteins from lysates of extracellular vesicles. Silver staining of extracellular vesicle
lysates obtained by different isolation methodologies from MKN45 (M) human gastric cancer cell line and glycoengineered MKN45
(gM) cultured 48 h with 1640 RPMI (-FBS) or with 1640 RPMI supplemented with 10% FBS (+FBS). The total cell lysates are also
shown. *These bands were identified with a high number of candidate peptides without reaching statistical significance.
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N-glycans (E-PHA and L-PHA) and fucosylated struc-
tures (AAL) were used. These lectins have been
recently used to disclose glycosylation profiles in dif-
ferent EV populations [5]. The EVs collected from
MKN45 using non-FBS supplemented medium dis-
played high molecular weight glycoproteins exhibiting
different degree of reactivity to the E-PHA and L-PHA
lectins, responsible for the detection of bisected and
branched N-glycans, respectively (Figure 7(b,c)).
Although to a lesser extent, these glycosylation patterns
were also detected in glycoproteins from EVs derived
from gMKN45 regarding E-PHA, but very faint reac-
tivity for L-PHA. Different bisected N-glycoproteins
were also detected by lectin affinity in the EVs isolated
in the presence of FBS. Regarding branched N-glycans,
detected with L-PHA, it was possible to identify high
molecular weight glycoproteins displaying these gly-
cans in EVs from MKN45 cells, which were not visible
in the EVs collected from the gMKN45 cells. When the
cells were cultured in the presence of FBS, a major
reactive band around 65 kDa precluded the detection
of less abundant proteins (Figure 7(b,c)). The reactivity
of the lectins E-PHA and L-PHA to this major band is
likely to result from non-specific lectin binding to BSA.
Supporting this, when UC was applied to medium
containing EV-depleted FBS but without any cell con-
tact, a major band of approximately 65 kDa was also
detected by E-PHA and L-PHA lectins. Remarkably, no
unspecific STn or fucosylation (AAL) detection was
observed (Figure 7, right panel).
Regarding AAL lectin reactivity, our results demon-
strated that the different isolation protocols enriched
Figure 6. Protein profile of extracellular vesicles (EVs) isolated by differential ultracentrifugation (UC), total exosome isolation (TEI),
OptiPrepTM density gradient (ODG) and size exclusion chromatography (SEC) from MKN45 (M) human gastric cancer cell line and
glycoengineered MKN45 (gM) cells. (a) Western blotting of HSP70, syntenin-1, CD9, CD63, Alix and CD81 extracellular vesicle
markers and cytochrome C mitochondria marker performed on total cell lysates and EV lysates in non-FBS supplemented medium or
(b) cells cultured with medium supplemented with 10% FBS. At least two independent experiments were conducted. (c) Western
blotting of syntenin-1, CD9 and CD63 EV markers on total cell lysates and EV lysates in non-FBS supplemented medium. EV samples
were isolated by UC or ODG followed by TEI.
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different EV subpopulations, both in MKN45 and
gMKN45 cell lines. This effect was observed in the
isolated EVs independently of the cell culture condi-
tions (Figure 7(d)).
Altogether, the UC, ODG and SEC methods resulted
in a similar EVs glycoprofile, illustrated by the STn and
lectin staining (Figure 7). Nevertheless, the signal
detection in the blots was increased in the EVs isolated
using the ODG and SEC protocols. On the other hand,
the ODG approach resulted in the isolation of EVs
with less contaminants from the FBS of the medium,
as observed by the lower reactivity at the BSA molecu-
lar weight (Figures 7 and 5). The TEI protocol showed
to be the least efficient to enrich in EV glycoproteins,
as evidenced by the lectin staining (Figure 7(b–d)). All
the tested methodologies were able to isolate, although
Figure 7. Glycan detection of extracellular vesicles obtained by differential ultracentrifugation (UC), total exosome isolation (TEI),
OptiPrepTM density gradient (ODG) and size exclusion chromatography (SEC) in the absence (-FBS) or presence (+FBS) of FBS in the
culture medium. Western blotting of total cell lysates and extracellular vesicle lysates secreted by MKN45 (M) human gastric cancer
cell line and glycoengineered MKN45 (gM) using (a) an anti-STn antibody (red dots indicate high molecular weight glycoproteins
displaying STn) and the different lectins (b) E-PHA, (c) L-PHA and (d) AAL. Glycan epitopes recognized by the lectins and the
antibody used are depicted (left panel). At least two independent experiments were conducted. The right panel shows the control
condition performed with total cell lysates and the pellet obtained after UC of medium supplemented with 10% FBS and without
cell contact. Abbreviations: STn: sialyl-Tn; AAL: Aleuria aurantia lectin; E-PHA: Phaseolus vulgaris erythroagglutinin; L-PHA: Phaseolus
vulgaris leucoagglutinin.
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to a different extent, glycosylated EVs from cancer cells
including glycoproteins bearing both N-glycans and
simple truncated O-glycans.
Different isolation methodologies result in distinct
proteomes of sialyl-Tn expressing extracellular
vesicles
The proteomic evaluation of the EVs from gMKN45 cells
revealed that protein cargo varies according to the EV
isolation protocol applied (Figure 8 and Supplementary
Table 2).
The proteomic analysis identified a total of 853 proteins
whereas 139 proteins (16.3%) were present in all EV sam-
ples independently of the isolation methodology applied.
This overlapping cargo included several human cancer-
related proteins and EVmarkers. In addition, a large num-
ber of proteins (n= 98; 11.5%)was identified in EV samples
obtained by UC, ODG and SEC. The EV protein content
obtained by these three methods (UC, ODG and SEC)
contained important cancer-related proteins as well as
known EV markers that TEI failed to isolate. Importantly,
additional EV markers were enriched in the samples iso-
lated by both ODG and SEC. Although all protocols iso-
lated EVs, each one enriched a unique set of proteins.
A large number of proteins was only detected in TEI (n =
172; 20.2%) and UC (n = 119; 14%) EV samples (Figure 8).
Further bioinformatic analysis using NetOGlyc 4.0
server showed that more than 80% of the identified EV
proteins are putatively O-glycosylated (Supplementary
Table 2). Interestingly, several glycoproteins previously
identified as carrying Tn/STn in the gMKN45 cells,
such as PDCD6I (Alix), LGALS3BP, GPC1, GPC4,
CDH1, CD44, ITGB1, MUC5AC and MET [40], were
also detected in gMKN45 secreted EVs (Figure 8).
Discussion
Glycosylation has proven to be crucial in a wide variety
of cancer cell processes, including tumour angiogen-
esis, immune response modulation, interaction with
tumour microenvironment and metastasis formation
[8]. Therefore, variations of the cellular surface glycans
have significant structural and functional consequences
for cancer cells, influencing the progression of the
disease and impacting patients’ prognosis [8].
Previous studies have demonstrated that EVs play
major roles in the horizontal transfer of material from
donor to recipient cells, thereby acting as important
intercellular communication tools in physiological and
pathological settings [1,2,48]. Furthermore, EVs have
been shown to be key players in the modulation and
establishment of the pre-metastatic niche, responsible
for cancer progression and metastasis [49–51].
Figure 8. Representation of the proteins identified from extracellular vesicles (EVs) isolated by differential ultracentrifugation (UC),
total exosome isolation (TEI), OptiPrepTM density gradient (ODG) and size exclusion chromatography (SEC) methodologies from
glycoengineered MKN45 cells grown in the absence of FBS. Venn diagram demonstrates the number (and percentage) of unique
and overlapping proteins identified by proteomic analysis for each EV isolation methodology. One experiment was conducted.
Boxes highlight key cancer-related proteins (framed in full line) or EV markers (framed in dotted line) identified in the EV samples.
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Accordingly, EVs displaying different ‘glycan coats’
hold the potential to differently interplay with other
cells within the tumour microenvironment as well as at
distant sites [52].
Despite the relevance of improving the knowledge
regarding the functional diversity of distinct EV sub-
types [53], previous studies evaluating the impact of
each EV isolation protocol, including the measurement
of the isolation efficiency and the yield, have been
mainly limited to the analysis of proteins, lipids and
nucleic acids (reviewed in [54]). To the best of our
knowledge, the impact of the isolation methodology
on the EV glycosylation profile has never been
reported.
In the present study, we took advantage of a unique
glycoengineered cancer cell model with previously fully
characterized O-glycoproteome, displaying homoge-
nous truncated O-glycosylation with expression of the
tumour-associated Tn and STn O-glycan structures
[40,55]. The analysis of the EVs secreted by this cell
model in comparison with the EVs produced by the
parental cell line allowed an accurate evaluation of how
the different isolation methods affect the enrichment of
differently glycosylated EV subpopulations. This cell
model proved to be of great importance since we
were able to demonstrate that the STn glycan, which
is a tumour-specific antigen associated with cancer cell
aggressiveness features and patients’ poor prognosis
[13,56], is present in the secreted EVs.
In addition to the evaluation of the impact that
different state-of-the-art methods for EVs isolation
have in the EV populations’ glycosylation profile, this
study has addressed how differences on cell culture
conditions, namely serum supplementation of the med-
ium, affect the purity of the isolated EVs.
When collecting EVs, it is important to use culture
medium supplemented with the minimum concentration
of serum since proteins, such as BSA, can non-specifically
bind to the EVs membranes and be co-purified [41,57].
Several bovine proteins were identified in the EV samples
isolated from cells growing in medium supplemented
with FBS. In particular, TEI led to the largest co-
isolation of BSA and ODG to the least. In this regard,
the FBS removal has been previously described as
a crucial step for EVs content analysis by mass spectro-
metry [58]. However, some cell lines are sensitive to the
complete removal of serum for their viable growth. In our
study, we show that 48 h of serum deprivation did not
cause significant alterations in cell viability. Considering
the abundance of glycosylated proteins in the FBS that
could interfere with the downstream EV glycosylation
analysis, we performed all the experiments in parallel
without FBS-supplemented medium. Our results are in
agreement with previous reports that disclosed FBS as
a major component when isolating EVs from medium
containing FBS, which interferes with the further study of
specific features of the cancer cell-derived EVs [59]. In
our present study, EVs were isolated through long cen-
trifugation protocols and therefore we cannot exclude
that shorter centrifugation times could reduce the pre-
sence of FBS soluble contaminants in the isolated EV
samples. Furthermore, we observed that for the same
amount of protein, a distinct EV protein profile could
be better discriminated when cells were grown in the
absence of FBS in the culture medium.
Previous studies have demonstrated that the selected
isolation method influences the yield and the func-
tional characteristics of the EV samples obtained [60].
Our evaluation by TEM imaging and NTA analysis
revealed that UC, TEI, ODG and SEC isolate hetero-
geneous EV populations in agreement with previous
reports [35,38,42].
Furthermore, each applied protocol was able to iso-
late EVs with distinct protein contents, as demon-
strated by the general protein profile and validated by
the global proteomic analysis as well as by specific EV
markers. In this study, following the recommendations
of the Society for Extracellular Vesicles, the character-
ization of the different EV-enriched samples included
transmembrane proteins (CD9, CD63 and CD81), the
cytoplasmic HSP70 and Alix proteins, and a cytosolic
protein with membrane binding capacity (syntenin-1),
as well as negative staining for an intracellular marker
(cytochrome C) [57]. The purification methods ODG
and SEC isolated the most similar EV populations. In
contrast, the least labour-intensive protocol TEI
resulted in the most distinct EVs. The absence/low
expression of CD9 in the TEI sample that we observed
is in accordance with previous reports [61].
Interestingly, when TEI was applied to previously UC
or ODG isolated EVs, it isolated EVs with comparable
EV markers detection as UC or ODG isolated samples.
However, when TEI was directly applied to condi-
tioned media co-precipitated soluble proteins together
with EVs, precluding the detection of some EV mar-
kers. These results highlight the importance of
a detailed characterization of the EV populations iso-
lated applying different techniques.
EV glycosylation analysis is a very challenging and
a recent emerging field of research [5,6]. There are still
few approaches for glycoconjugate content analysis,
which are particularly relevant for the biogenesis,
secretion and uptake of the EVs [27–33]. Different
approaches using lectins are being developed to selec-
tively enrich in EV subpopulations with specific glycan
content [62]. The present work evidences the relevance
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of the methodology applied towards a biased-
enrichment in the assortment of glycosylated EV popu-
lations. Overall, the tested protocols, UC, TEI, ODG
and SEC were successful in isolating EVs carrying
glycoproteins bearing N-linked and truncated
O-linked glycans, although leading to the enrichment
of different EV subpopulations. ODG and SEC proto-
cols add a purification step to the UC isolation, which
resulted in an improved detection of the EVs glycosy-
lation. TEI methodology enriched in EV populations
carrying less detectable glycoproteins. Remarkably,
changing the glycosylation of the MKN45 cells towards
the expression of the cancer-associated STn glycan, also
impacted the glycosylation of the isolated EVs. The
evaluation of other glycosylation determinants, such
as bisected and branched N-glycans, detected by
E-PHA and L-PHA, as well as fucosylation detected
by AAL, further indicated differences in the enriched
EVs glycoprofile depending on the method applied for
isolation. These results further support the previously
known cargo specificity characteristics of EVs. Previous
reports demonstrated that specific glycosylation signa-
tures were detected in EVs, including large and small
exosomes, relative to plasma membrane or microsomal
glycoproteins [63,64], as well as in the recently
described exomere subpopulation [5]. The cellular
synthesis of STn has been shown to promote an aggres-
sive malignant phenotype and is often associated with
poor prognosis of gastric cancer patients [14].
Interestingly, the EVs derived from the gMKN45 were
enriched on specific high molecular weight glycopro-
teins carrying the STn antigen, when compared with
the whole gMKN45 cellular lysate. Moreover, our pro-
teomic results showed that EVs displaying STn carried
several cancer-related proteins. More than 80% of the
identified proteins were predicted to be O-glycosylated.
Furthermore, proteins previously demonstrated to dis-
play STn in the gMKN45 cells [40] were detected in the
EV samples. Noteworthy, a considerable set of cancer-
related proteins and EV markers were identified by
UC, ODG and SEC which were not detected in the
TEI isolated sample. This observation is in agreement
with the distinct STn profile of the TEI sample, sup-
porting different STn carriers. The large number of
proteins exclusively identified in TEI may reflect the
co-isolation of non-EV proteins. Moreover, the identi-
fication of additional EV markers in the samples iso-
lated by ODG and SEC reflected a more pure EV
population, highlighting the positive impact of ODG
and SEC purification steps after UC. Therefore,
a thorough EV purification strategy, such as UC fol-
lowed by ODG or SEC, is required for EV glycosylated
biomarkers discovery.
The potential applications of the EVs in the clinical
setting have been proposed, mostly due to their pro-
mising utility in the diagnosis and prognosis of several
diseases [65,66]. Furthermore, the secretion of EVs
with defined glycan profile into body fluids makes
them a valuable source of biomarkers for non-
invasive diagnosis. Nevertheless, prior to this imple-
mentation, the isolation methods need to be
standardized.
In conclusion, the analysis of the glycosylation pat-
tern of the proteins carried by EVs isolated from cancer
cells uncovered that the different isolation approaches
result in different EV subpopulations. UC, ODG and
SEC methods isolated EVs with similar protein and
glycan contents, allowing the detection of the tumour-
associated glycan antigen STn. The TEI technique
enriched the most different EV population and pre-
sented the higher content of non-EV co-purified pro-
teins. Given the importance that EVs have in
transporting specific cargo between cells, including
cancer cells, and the recognized role of glycans in
tumour progression, it is of major interest that future
studies take into account the populations of EVs dis-
playing diverse glycosylation profiles when addressing
the roles and functional diversity of these particles.
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